Longevity, telomere biology, circadian rhythm, melatonin regulation, cellular ag
Epitalon (Epithalon)
A synthetic pineal tetrapeptide studied for telomere biology, circadian and melatonin regulation, cellular aging, oxidative stress, retinal function, and broader longevity-related mechanisms.
Administration Reference
Subcutaneous
Source / Evidence Context
Commonly reported use — not established guidance
Formulation & Context
Synthetic tetrapeptide (Ala-Glu-Asp-Gly/AEDG). (not to be confused with Epithalamin)
Dose Information
0.5mg starting for 3 days then 1 mg
Frequency
once daily
Duration / Cycle
10–15 days
Off-Cycle
4–6 months often repeated 1–2 times per year
Timing
Evening or before bed
Storage Guidance
Refrigerate after reconstitution and use within approximately 30 days, Freeze for lyophilized powder form
Supplies
Affiliate disclosure: We may earn a commission if you purchase through these links.
Listings are not a required kit or confirmation of suitability for a particular peptide, formulation, or route. Check the product specifications and intended use.
Syringes & transfer supplies
Exlavges 100 Pack Disposable 3ml/cc Lab Syringes23Ga 1 Inch Needle Luer LockIndividually Sealed PackedView at Amazon →
EasyTouch U-100 Insulin Syringes (31G 0.5cc 5/16″) – 100ct.U-100 Insulin Syringes (31G 0.5cc 5/16") – 100ctInsulin syringes – Polybag, 50 Unit Capacity, 5/16” Needle Length, Bold Markings for Accurate Dosing, Disposable, Box of 100View at AMAZON →
Protective supplies & disposal
MED PRIDE Sterile Alcohol Prep Pads1 BOX OF 200INDIVIDUALLY WRAPPED ISOPROPYL ALCOHOL WIPES, PACK OF 1 BOX OF 200, MEDIUM SIZE PREP PADSView at AMAZON →
Square Sharps Container, 2 QuartQTY 1View at AMAZON →
Inspire Black Nitrile Gloves HEAVY DUTY 6 Mil100ctView at AMAZON →
Commonly Reported Uses
Longevity and healthy-aging research; telomere maintenance; circadian-rhythm and sleep-related research; melatonin regulation; cellular stress resistance; antioxidant activity; immune-aging research; retinal and neuroendocrine research.
Commonly Reported Indicators
Community reports commonly focus on improved sleep regularity, deeper or more consistent sleep, changes in dream intensity, improved daytime energy, reduced perceived fatigue, and improved general well-being. Research endpoints have included melatonin metabolites, circadian hormone patterns, telomere length, cellular replication, retinal function, oxidative-stress markers, and lifespan outcomes.
Mechanism Overview
Epitalon has demonstrated effects on telomerase expression and activity, telomere elongation, circadian gene expression, melatonin regulation, antioxidant pathways, and cellular stress signaling. Its best-known mechanism is activation of telomerase in aging somatic cells, although multiple additional regulatory mechanisms are under investigation.
Safety
Safety Considerations
Available human reports have not identified a clear pattern of serious adverse events, but systematic safety monitoring is limited. FDA’s 2026 review identified no FAERS adverse-event reports through December 2025 while emphasizing potential concerns involving peptide aggregation, immunogenicity, impurities, and limited characterization of injectable formulations.
Reported Adverse Effects
Community-reported effects include temporary injection-site redness, soreness or swelling, headache, fatigue, altered sleep patterns or vivid dreams, and occasional dizziness. Reliable incidence rates are unavailable. Injection-related risks also depend substantially on sterility, purity, concentration, and product handling.
Contraindications & Cautions
Particular caution is appropriate with active malignancy, pregnancy or breastfeeding, known peptide hypersensitivity, significant unexplained illness, and concurrent cancer therapy. Telomerase-related mechanisms make oncology history especially relevant despite conflicting preclinical cancer findings.
Cancer Considerations
Editorial evidence assessment, not a validated risk score or clearance for use. Unknown risk does not mean low risk; these notes do not establish safety during active cancer or remission.
Cancer Concern Assessment
Theoretical concern
Basis for Concern
Epitalon can activate telomerase and increase telomere length in human cell models. Telomerase is also used by many cancers to maintain replicative capacity, creating a plausible theoretical concern. Importantly, animal experiments have not demonstrated increased spontaneous cancer from Epitalon and several reported reductions in malignant tumors or metastasis.
Active Cancer
Caution due to mechanism
Because telomerase activation could theoretically support the survival or replicative capacity of existing malignant cells, active cancer warrants substantial caution. This concern is mechanistic rather than based on evidence that Epitalon accelerates human cancer. Animal studies have instead reported neutral or favorable tumor outcomes, underscoring the uncertainty rather than establishing safety.
Prior Cancer / Remission
Individualized caution
No validated remission interval has been established. The telomerase mechanism supports individualized caution, while available animal studies do not show a consistent carcinogenic signal. Prior cancer type, recurrence risk, and ongoing surveillance remain relevant considerations.
Status
Regulatory Status
Epitalon is not an FDA-approved drug. FDA evaluated Epitalon free base and Epitalon acetate in July 2026 for possible inclusion on the 503A Bulks List, specifically reviewing insomnia as the proposed use. FDA staff recommended against inclusion based on characterization, safety, immunogenicity, and effectiveness concerns.
Development / Research Status
Human research compound
Market Classification
Research-use compound
Status Notes
The Pharmacy Compounding Advisory Committee subsequently voted to recommend Epitalon for inclusion on the 503A Bulks List, contrary to FDA staff’s recommendation. The committee vote is advisory and does not itself add Epitalon to the list or constitute FDA approval.
Research & Evidence
Evidence Level
Human clinical research
Research Last Reviewed
2026-09-06
Research Overview
Epitalon has a broad but uneven research history spanning cellular telomere studies, animal longevity models, neuroendocrine research, retinal studies, and limited human investigations. Evidence supporting telomerase activation is strong at the cellular level, while human longevity claims remain much less established. More recent independent research has reproduced telomere-length effects in human cell lines.
Human Research
A randomized placebo-controlled study in 75 women aged 40–50 working predominantly night shifts included 40 participants with reduced melatonin production. Twenty days of sublingual AEDG at 0.5 mg/day increased urinary 6-sulfatoxymelatonin approximately 1.7-fold and restored levels toward age-appropriate values. Researchers also reported improved general and psycho-emotional condition in 83% of treated participants versus 25% with placebo, although direct sleep outcomes were not measured.
A separate publication involving 162 patients with retinitis pigmentosa reported improved retinal bioelectrical and functional activity following a 10-day Epitalon treatment course, with a positive clinical response reported in approximately 90% of cases. The specialized parabulbar administration used in this research is not comparable with community subcutaneous protocols.
Several frequently cited human longevity studies involve Epithalamin, the original pineal peptide extract, rather than synthetic Epitalon itself. Those results provide related biological context but should not be treated as direct proof of Epitalon’s longevity effects.
Animal Research
In female SHR mice, long-term Epitalon treatment did not significantly increase mean lifespan but increased maximum lifespan by approximately 12.3% and lifespan among the longest-lived 10% by 13.3%. Chromosomal abnormalities declined, total spontaneous tumor incidence was unchanged, and leukemia occurred less frequently.
Other mouse experiments reported delayed reproductive aging, altered oxidative-stress markers, longer survival in selected models, and reduced malignant tumor or metastatic development. Drosophila research reported lifespan increases of approximately 11–16% at very low concentrations.
In aged rhesus monkeys, Epitalon increased evening melatonin and restored a more youthful circadian cortisol pattern, supporting its proposed pineal and neuroendocrine effects.
In Vitro Research
A 2003 study reported that Epitalon induced expression of the catalytic component of telomerase, increased telomerase activity, and elongated telomeres in human fetal fibroblasts. Follow-up work found Epitalon-treated aging fibroblasts underwent approximately 10 additional population doublings beyond untreated cells.
In 2025, independent investigators reported telomere elongation across human cell lines following Epitalon exposure, with evidence that effects could involve telomerase upregulation or alternative lengthening of telomeres depending on cell type.
References
Khavinson VK, Bondarev IE, Butyugov AA. Epithalon peptide induces telomerase activity and telomere elongation in human somatic cells. Bull Exp Biol Med. 2003;135(6):590-592. PMID 12937682. DOI 10.1023/A:1025493705728.
Khavinson VK, Bondarev IE, Butyugov AA, Smirnova TD. Peptide promotes overcoming of the division limit in human somatic cell. Bull Exp Biol Med. 2004;137(5):503-506. PMID 15455129. DOI 10.1023/B:BEBM.0000038164.49947.8c.
Al-Dulaimi S, Thomas R, Matta S, Roberts T. Epitalon increases telomere length in human cell lines through telomerase upregulation or ALT activity. Biogerontology. 2025;26(5):178. PMID 40908429. DOI 10.1007/s10522-025-10315-x.
Khavinson VK, et al. Pineal-regulating tetrapeptide Epitalon improves eye retina condition in retinitis pigmentosa. Neuro Endocrinol Lett. 2002;23(4):365-368. PMID 12195242.
Khavinson VK, Goncharova N, Lapin B. Synthetic tetrapeptide Epitalon restores disturbed neuroendocrine regulation in senescent monkeys. Neuro Endocrinol Lett. 2001;22(4):251-254. PMID 11524632.
Khavinson VK, et al. Peptides and ageing. Neuro Endocrinol Lett. 2002. PMID 12374906.
Anisimov VN, Khavinson VK, Popovich IG, et al. Effect of Epitalon on biomarkers of aging, life span and spontaneous tumor incidence in female Swiss-derived SHR mice. Biogerontology. 2003;4(4):193-202. PMID 14501183. DOI 10.1023/A:1025114230714.
Anisimov VN, et al. Effect of pineal peptide on parameters of biological age and life span in mice. 2001. PMID 11227856.
Anisimov VN, et al. Effect of Epitalon and melatonin on life span and spontaneous carcinogenesis in senescence-accelerated mice. 2005. PMID 15909815.
Kossoy G, Anisimov VN, Ben-Hur H, et al. Effect of the synthetic pineal peptide Epitalon on spontaneous carcinogenesis in female C3H/He mice. In Vivo. 2006;20(2):253-257. PMID 16634527.
Anisimov VN, et al. Effect of Epitalon on the lifespan increase in Drosophila melanogaster. Mech Ageing Dev. 2000. PMID 11087911. DOI 10.1016/S0047-6374(00)00217-7.
Yue X, Liu SL, Guo JN, et al. Epitalon protects against post-ovulatory aging-related damage of mouse oocytes in vitro. Aging. 2022;14(7):3191-3202. PMID 35413689. DOI 10.18632/aging.204007.
Overview of Epitalon—Highly Bioactive Pineal Tetrapeptide with Promising Properties. 2025. PMID 40141333.
U.S. Food and Drug Administration. Epitalon-Related Bulk Drug Substances — Pharmacy Compounding Advisory Committee Briefing Document. July 2026.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks — Epitalon. Updated 2026.
U.S. Food and Drug Administration. July 23–24, 2026 Pharmacy Compounding Advisory Committee Meeting — Epitalon free base and Epitalon acetate.
Peptide Protocol Wiki. Epitalon Dosing Protocols and Administration. Updated January 2026.
ResearchProtocols.net. Epitalon Reference Protocols — community microgram and classic dosing schedules. 2026.